These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 22695620)

  • 21. Chapter 3 - Colloidal systems for CNS drug delivery.
    Costantino L; Tosi G; Ruozi B; Bondioli L; Vandelli MA; Forni F
    Prog Brain Res; 2009; 180():35-69. PubMed ID: 20302828
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The therapeutic use of gene therapy in inflammatory demyelinating diseases of the central nervous system.
    Furlan R; Pluchino S; Martino G
    Curr Opin Neurol; 2003 Jun; 16(3):385-92. PubMed ID: 12858077
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Theranostical application of nanomedicine for treating central nervous system disorders.
    Ran W; Xue X
    Sci China Life Sci; 2018 Apr; 61(4):392-399. PubMed ID: 29675554
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Blood-brain barrier permeability considerations for CNS-targeted compound library design.
    Hitchcock SA
    Curr Opin Chem Biol; 2008 Jun; 12(3):318-23. PubMed ID: 18435937
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Polymeric nanoparticles for the drug delivery to the central nervous system.
    Tosi G; Costantino L; Ruozi B; Forni F; Vandelli MA
    Expert Opin Drug Deliv; 2008 Feb; 5(2):155-74. PubMed ID: 18248316
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Recent advances in the rational design of silica-based nanoparticles for gene therapy.
    Niut Y; Popatt A; Yu M; Karmakar S; Gu W; Yu C
    Ther Deliv; 2012 Oct; 3(10):1217-37. PubMed ID: 23116013
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prodrug approaches to reduce hyperexcitation in the CNS.
    Vytla D; Combs-Bachmann RE; Hussey AM; McCarron ST; McCarthy DS; Chambers JJ
    Adv Drug Deliv Rev; 2012 May; 64(7):666-85. PubMed ID: 22138074
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Applications of a blood-brain barrier technology platform to predict CNS penetration of various chemotherapeutic agents. 2. Cationic peptide vectors for brain delivery.
    Adenot M; Merida P; Lahana R
    Chemotherapy; 2007; 53(1):73-6. PubMed ID: 17202815
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Polymeric nanoparticles - targeted drug delivery systems for treatment of CNS disorders and their possible endocrine disrupting activities.
    Rollerova E; Scsukova S; Jurcovicova J; Mlynarcikova A; Szabova E; Kovriznych J; Zeljenkova D
    Endocr Regul; 2011 Jan; 45(1):49-60. PubMed ID: 21314211
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Central nervous system penetration for small molecule therapeutic agents does not increase in multiple sclerosis- and Alzheimer's disease-related animal models despite reported blood-brain barrier disruption.
    Cheng Z; Zhang J; Liu H; Li Y; Zhao Y; Yang E
    Drug Metab Dispos; 2010 Aug; 38(8):1355-61. PubMed ID: 20427691
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sonic hedgehog intradermal gene therapy using a biodegradable poly(β-amino esters) nanoparticle to enhance wound healing.
    Park HJ; Lee J; Kim MJ; Kang TJ; Jeong Y; Um SH; Cho SW
    Biomaterials; 2012 Dec; 33(35):9148-56. PubMed ID: 23018131
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Time-dependent translocation and potential impairment on central nervous system by intranasally instilled TiO(2) nanoparticles.
    Wang J; Liu Y; Jiao F; Lao F; Li W; Gu Y; Li Y; Ge C; Zhou G; Li B; Zhao Y; Chai Z; Chen C
    Toxicology; 2008 Dec; 254(1-2):82-90. PubMed ID: 18929619
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Potential of solid lipid nanoparticles in brain targeting.
    Kaur IP; Bhandari R; Bhandari S; Kakkar V
    J Control Release; 2008 Apr; 127(2):97-109. PubMed ID: 18313785
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Characterization of a multifunctional PEG-based gene delivery system containing nuclear localization signals and endosomal escape peptides.
    Moore NM; Sheppard CL; Sakiyama-Elbert SE
    Acta Biomater; 2009 Mar; 5(3):854-64. PubMed ID: 18926782
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Translating the therapeutic potential of neurotrophic factors to clinical 'proof of concept': a personal saga achieving a career-long quest.
    Bartus RT
    Neurobiol Dis; 2012 Nov; 48(2):153-78. PubMed ID: 22525569
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The targeted delivery of cancer drugs across the blood-brain barrier: chemical modifications of drugs or drug-nanoparticles?
    Juillerat-Jeanneret L
    Drug Discov Today; 2008 Dec; 13(23-24):1099-106. PubMed ID: 18848640
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neurological disorders and therapeutics targeted to surmount the blood-brain barrier.
    Kanwar JR; Sriramoju B; Kanwar RK
    Int J Nanomedicine; 2012; 7():3259-78. PubMed ID: 22848160
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Acid-degradable cationic methacrylamide polymerized in the presence of plasmid DNA as tunable non-viral gene carrier.
    Ko IK; Ziady A; Lu S; Kwon YJ
    Biomaterials; 2008 Oct; 29(28):3872-81. PubMed ID: 18585778
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Transgene expression in the brain stem effected by intramuscular injection of polyethylenimine/DNA complexes.
    Wang S; Ma N; Gao SJ; Yu H; Leong KW
    Mol Ther; 2001 May; 3(5 Pt 1):658-64. PubMed ID: 11356070
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Brain-directed gene therapy for lysosomal storage disease: going well beyond the blood- brain barrier.
    Sly WS; Vogler C
    Proc Natl Acad Sci U S A; 2002 Apr; 99(9):5760-2. PubMed ID: 11983877
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.